Arcturus Therapeutics Holdings Inc [ARCT] stock is trading at $20.47, down -2.57%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARCT shares have gain 11.07% over the last week, with a monthly amount glided 14.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 28, 2025, and set its price target to $32. On January 28, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $41 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $70 on August 12, 2024. Canaccord Genuity initiated its recommendation with a Buy and recommended $90 as its price target on December 13, 2023. William Blair started tracking with a Outperform rating for this stock on July 24, 2023, and assigned it a price target of $71. In a note dated May 11, 2023, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $19 to $51.
Arcturus Therapeutics Holdings Inc [ARCT] stock has fluctuated between $8.04 and $24.13 over the past year. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Arcturus Therapeutics Holdings Inc [NASDAQ: ARCT] shares were valued at $20.47 at the most recent close of the market. An investor can expect a potential return of 110.06% based on the average ARCT price forecast.
Analyzing the ARCT fundamentals
Arcturus Therapeutics Holdings Inc [NASDAQ:ARCT] reported sales of 109.80M for the trailing twelve months, which represents a drop of -46.69%. Gross Profit Margin for this corporation currently stands at 0.45% with Operating Profit Margin at -0.62%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.25 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.92 points at the first support level, and at 19.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.31, and for the 2nd resistance point, it is at 22.14.
Ratios To Look Out For
For context, Arcturus Therapeutics Holdings Inc’s Current Ratio is 5.90. Further, the Quick Ratio stands at 5.90, while the Cash Ratio is 4.22. Considering the valuation of this stock, the price to sales ratio is 5.06, the price to book ratio is 2.41.
Transactions by insiders
Recent insider trading involved Chivukula Pad, Chief Scientific Officer & COO, that happened on Oct 15 ’24 when 12000.0 shares were sold. Officer, Chivukula Pad completed a deal on Oct 15 ’24 to buy 12000.0 shares.
